Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma | Zendy

Sarah M. Ward | Zendy; Matthew Skinner | Zendy; Banishree Saha | Zendy; Todd Emrick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma

Author(s) -

Sarah M. Ward,

Matthew Skinner,

Banishree Saha,

Todd Emrick

Publication year - 2018

Publication title -

molecular pharmaceutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.13

H-Index - 127

eISSN - 1543-8392

pISSN - 1543-8384

DOI - 10.1021/acs.molpharmaceut.8b00766

Subject(s) - temozolomide , copolymer , chemistry , polymer , polymerization , methacrylate , monomer , chain transfer , conjugate , dispersity , dynamic light scattering , polymer chemistry , combinatorial chemistry , materials science , radical polymerization , nanotechnology , organic chemistry , nanoparticle , glioblastoma , cancer research , mathematical analysis , mathematics , biology

A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups. Random and block copolymers were synthesized by reversible addition-fragmentation chain-transfer (RAFT) polymerization using a TMZ-containing methacrylate monomer. The solution properties of the polyMPC-TMZ copolymers were investigated by dynamic light scattering and transmission electron microscopy, revealing well-defined nanostructures from the block copolymers. Conjugation of TMZ to polyMPC enhanced drug stability, with decomposition half-life values ranging from 2- to 19-times longer than that of free TMZ. The cytotoxicity of polyMPC-TMZ was evaluated in both chemosensitive (U87MG) and chemoresistant (T98G) glioblastoma cell lines. Furthermore, the polyMPC-TMZ platform was expanded considerably by the preparation of redox-sensitive polyMPC-TMZ copolymers utilizing disulfides as the polymer-to-drug linker.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research